186 related articles for article (PubMed ID: 34878632)
21. Efficacy of ivabradine in HIV-associated dilated cardiomyopathy.
Mastroianni A; Guadagnino G; Vangeli V; Greco S; Urso F
Recenti Prog Med; 2021 Apr; 112(4):311-314. PubMed ID: 33877092
[TBL] [Abstract][Full Text] [Related]
22. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice.
Perings S; Stöckl G; Kelm M;
Adv Ther; 2016 Sep; 33(9):1550-64. PubMed ID: 27432382
[TBL] [Abstract][Full Text] [Related]
24. Ivabradine for treatment of heart failure.
Bocchi EA; Salemi VMC
Expert Opin Drug Saf; 2019 May; 18(5):393-402. PubMed ID: 31074301
[TBL] [Abstract][Full Text] [Related]
25. Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.
Ye F; Wang X; Wu S; Ma S; Zhang Y; Liu G; Liu K; Yang Z; Pang X; Xue L; Lu S; Zhong M; Li J; Yu H; Lou D; Cui D; Xie X; Wang J;
J Am Coll Cardiol; 2022 Aug; 80(6):584-594. PubMed ID: 35926931
[TBL] [Abstract][Full Text] [Related]
26. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials.
Bryan Richard S; Huang B; Liu G; Yang Y; Luo S
Clin Cardiol; 2021 Apr; 44(4):463-471. PubMed ID: 33638556
[TBL] [Abstract][Full Text] [Related]
27. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
[TBL] [Abstract][Full Text] [Related]
28. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
[TBL] [Abstract][Full Text] [Related]
29. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
Heart; 2014 Jul; 100(13):1031-6. PubMed ID: 24634022
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
[TBL] [Abstract][Full Text] [Related]
32. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
Bouabdallaoui N; O'Meara E; Bernier V; Komajda M; Swedberg K; Tavazzi L; Borer JS; Bohm M; Ford I; Tardif JC
ESC Heart Fail; 2019 Dec; 6(6):1199-1207. PubMed ID: 31591826
[TBL] [Abstract][Full Text] [Related]
34. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
Foster JL; Bobadilla RV
J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
[TBL] [Abstract][Full Text] [Related]
35. Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine.
Raja DC; Kapoor A; Sinha A; Kashyap S; Khanna R; Kumar S; Garg N; Tewari S; Goel P
Indian Heart J; 2018; 70(2):246-251. PubMed ID: 29716702
[TBL] [Abstract][Full Text] [Related]
36. Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study.
Zachariah D; Stevens D; Sidorowicz G; Spooner C; Rowell N; Taylor J; Kay R; Salek MS; Kalra PR;
Int J Cardiol; 2017 Dec; 249():313-318. PubMed ID: 29121732
[TBL] [Abstract][Full Text] [Related]
37. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure.
Sargento L; Satendra M; Longo S; Lousada N; dos Reis RP
Am J Cardiovasc Drugs; 2014 Jun; 14(3):229-35. PubMed ID: 24452599
[TBL] [Abstract][Full Text] [Related]
38. Effects of Heart Rate Reduction With Either Pyridostigmine or Ivabradine in Patients With Heart Failure: A Randomized, Double-Blind Study.
Villacorta AS; Villacorta H; Caldas JA; Precht BC; Porto PB; Rodrigues LU; Neves M; Xavier AR; Kanaan S; Mesquita CT; da Nóbrega ACL
J Cardiovasc Pharmacol Ther; 2019 Mar; 24(2):139-145. PubMed ID: 30198318
[TBL] [Abstract][Full Text] [Related]
39. PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
Mentz RJ; DeVore AD; Tasissa G; Heitner JF; Piña IL; Lala A; Cole RT; Lanfear DD; Patel CB; Ginwalla M; Old W; Salacata AS; Bigelow R; Fonarow GC; Hernandez AF
Am Heart J; 2020 May; 223():98-105. PubMed ID: 32217365
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
